Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Annexon, Inc. executive vice president and chief innovation officer Ted Yednock reported an open-market sale of 5,566 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. The sale was made to cover tax withholding obligations from vesting RSUs, leaving him with 154,161 directly owned shares.
Annexon, Inc. executive vice president and chief scientific officer Dean Richard Artis sold 5,894 shares of common stock on March 2, 2026 in an open-market transaction to cover tax withholding obligations from vested restricted stock units. The weighted average sale price was $5.43 per share, and he held 180,093 shares afterward.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 5,565 shares of common stock at a weighted average price of $5.42 per share. The shares were sold on March 2, 2026 to cover tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, she held 170,700 shares of Annexon common stock directly.
ANNX proposed sale of 5,566 common shares under a Form 144, tied to restricted stock vesting dated 02/27/2026.
The excerpt also shows a prior sale of 7,857 common shares on 02/18/2026 and a reported share count of 119,632,804 as of 03/02/2026.
ANNX reports a Rule 144 notice listing 5,894 common shares to be sold by the holder and 5,290 shares sold in the past three months. The filing names Fidelity Brokerage Services LLC as the broker/holder and shows the transaction type as Restricted Stock Vesting with the action labeled Compensation.
ANNX submitted a Rule 144 notice relating to proposed sales of its Common stock. The filing lists 4,339 Common shares tied to restricted stock vesting dated 02/27/2026 and discloses that Michael Overdorf sold 6,225 Common shares on 02/18/2026 with a reported amount of $31,764.30.
ANNX filed a Form 144 notice stating an intended sale of 5,820 common shares under Rule 144 on 02/27/2026 tied to restricted stock vesting. The filing also records a prior sale of 5,290 shares on 02/18/2026 by Jamie Dananberg.
ANNX submitted a Form 144 notice relating to 5,565 common shares associated with Fidelity Brokerage Services LLC, with a record row showing 03/02/2026 and NASDAQ.
The filing also lists a restricted stock vesting event dated 02/27/2026 tied to 5,565 shares (labeled "Compensation"), and a prior sale by Jennifer Lew of 7,851 common shares on 02/18/2026 with an adjacent figure of 40119.40.
Love Douglas reported acquisition or exercise transactions in this Form 4 filing.
Annexon, Inc. director and President & CEO Douglas Love reported receiving a grant of stock options covering 1,250,000 shares of the company’s stock. These are derivative securities, reflecting an equity incentive award rather than an open-market share purchase or sale.
According to the vesting terms, 1/48th of the option shares vest on each monthly anniversary starting on February 19, 2026, so the award becomes fully vested and exercisable on the fourth anniversary of that date. Vesting depends on Mr. Love’s continuous service with Annexon on each vesting date.
Annexon, Inc. reported that its Chief Medical Officer, Jamie Dananberg, received new equity awards on February 19, 2026. The awards include a stock option covering 225,000 shares at an exercise price of $0.00 per share and a grant of 56,250 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, 1/48 of the option shares vest monthly starting from February 19, 2026, becoming fully vested on the fourth anniversary, subject to continued service. For the RSUs, one-third vests each year on February 19, with the first third vesting on February 19, 2027, also conditioned on continuous service. Following these grants, Dananberg directly owns 129,402 shares of common stock.